Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain

Journal of Pain Research

Volumn 7, Issue , 2014, Pages 495-503

  Skaer, Tracy L ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Analgesic pharmacotherapy; Breakthrough pain; Equipotency ratio; Immediate release medication; Opioid withdrawal; Opioids; Pain treatment modification

Indexed keywords

BUPRENORPHINE; CODEINE; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; OXYCODONE;

CANCER PAIN; CENTRAL NERVOUS SYSTEM DISEASE; CONSTIPATION; DERMATITIS; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOVENTILATION; INCIDENCE; LOW DRUG DOSE; MEDICATION COMPLIANCE; NAUSEA; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT SATISFACTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATION DEPRESSION; REVIEW; SKIN IRRITATION; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE RETENTION; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 84906351015     PISSN: None     EISSN: 11787090     Source Type: Journal    
DOI: 10.2147/JPR.S36446     Document Type: Review

References (64)

1. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994;330(9):592-596.
2. Van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past40 years. Ann Oncol. 2007;18(9): 1437-1449.
3. Mercadante S, Fultaro F. World Health Organization guideline: a reappraisal. Ann Oncol. 2005;16(Suppl4):iv132-iv135.
4. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58-e68.
5. Quigley C. The role of opioids in cancer pain. BMJ.2005;331(7520): 825-829.
6. Hui D, Bruera E. Transdermal fentanyl: not ready for front line. J Palliat Care. 2009;25(4):300.
7. Tassinari D, Drudi F, Rosati M, Maltoni M. Transdermal opioids as front line treatment of moderate to severe cancer pain: a systemic review. Palliat Med. 2011;25(5):478-487.
8. Wiffen PJ, McQuay HJ. Oral morphine for cancer pain. Cochrane Database Syst Rev. 2007;(4):CD003868.
9. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management: stepping up the quality of its evaluation. JAMA. 1995;274(23):1870-1873.
10. Cachia E, Ahmedzai SH. Transdermal opioids for cancer pain. Curr Opin Support Palliat Care. 2011;5(1):15-19.
11. Tassinari D, Sartori S, Tamburini E, et al. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med. 2008;11(3):492-501.
12. Tassinari D, Sartori S, Tamburini E, et al. Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials. J Pallliat Care. 2009;25(3):172-180.
13. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32(4):304-315.
14. Dale O, Moksnes K, Kaasa S. European Palliative Care Research Collaborative pain guidelines: opioid switching to improve analgesia or reduce side-effects. A systematic review. Palliat Med. 2011;25(5): 494-503.
15. de Stoutz N, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage. 1995;10(5):378-384.
16. Bruera E, Pereira J, Watanabe S, Belzile M, et al. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer. 1996;78(4):852-857.
17. Mercadante S. Opioid rotation in cancer pain: rationale and clinical aspects. Cancer. 1999;86(9):1856-1866.
18. Mercadente S, Porzio G, Ferrera P, et al. Sustained release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain. 2008;12(8):1040-1046.
19. Wolff RF, Aune D, Truyers C, et al. Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. Curr Med Res Opin. 2012;28(5): 833-845.
20. Koyyalagunta D, Bruera E, Solanki DR, et al. A systematic review of randomized trials on the effectiveness of opioids in cancer pain. Pain Physician. 2012;15(Suppl 3):ES39-ES58.
21. Slatkin NE. Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin. 2009;25(9):2133-2150.
22. Skaer TL. Transdermal opioids for cancer pain. Health Qual Life Outcomes. 2006;4:24.
23. Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med. 2011;25(5): 504-515.
24. Bradley AM, Valgus JM, Bernard S. Converting transdermal fentanyl: avoidance of underdosing. J Palliat Med. 2013;16(4):409-411.
25. Ashburn M, Lipman A. Management of pain in the cancer patient. Anesth Analg. 1993;76(2):402-416.
26. Fine PG, Portenoy RK. Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing best practices for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38(3):418-425.
27. Knotkova H, Fine PF, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage. 2009;38(3):426-439.
28. Hanks GW, Fallon MT. Transdermal fentanyl in cancer pain. Conversion from oral morphine. J Pain Symptom Manage. 1995;10(2):87.
29. Webster LR, Fine PG. Overdose deaths demand a new paradigm for opioid rotation. Pain Med. 2012;13(4):571-574.
30. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet. 2000;38(1):59-89.
31. Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: A multicenter study in patients with cancer pain. Pain. 1996;64(3):527-534.
32. Radbruch L, Elsner F. Clinical experience with transdermal fentanyl for the treatment of cancer pain in Germany. Keio J Med. 2004;53(1): 23-29.
33. Mystakidou K, Parpa E, Tsilika E, et al. Pain management of cancer patients with transdermal fentanyl: a study of1828 step I, II, and III transfers. J Pain. 2004;5(2):119-132.
34. Mercadante S, Casuccio A, Tirelli W, Giarrantano A. Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Support Care Cancer. 2009;17(6):715-718.
35. Mercadante S, Porzio G, Fulfano F, et al. Switching from transdermal drugs: an observational 'N of1' study of fentanyl and buprenorphine. J Pain Symptom Manage. 2007;34(5):532-538.
36. Aurilio C, Pace MC, Pota V, et al. Opioids switching with transdermal systems in chronic cancer pain. J Ex Clini Cancer Res. 2009;28:61.
37. Sitti R, Likar R, Nautrup BP. Equipotent dose of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther. 2005;27(2): 225-237.
38. Freye E, Anderson-Hillemacher A, Ritzdorf I, Levy JV. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain Pract. 2007;7(2):123-129.
39. Likar R, Krainer B, Sitti R. Challenging the equipotency calculation for transdermal buprenorphine: four case studies. Int J Clin Pract. 2008;62(1):152-156.
40. Davies AN, Dickman A, Reid C, et al. The management of cancerrelated breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13(4):331-338.
41. Haugen DF, Hjermstad MJ, Hagen N, et al. Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain. 2010;149(3):476-482.
42. Kornick CA, Santiago-Palma J, Moryl N. et al. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf. 2003;26(13):951-973.
43. Breitbart W, Chandler S, Eagel B, et al. An alternative algorithm for dosing of transdermal fentanyl for cancer-related pain. Oncology (Williston Park).2000;14(5):695-705.
44. Payne R, Chandler S, Einhaus M. Guidelines for the clinical use of transdermal fentanyl. Anticancer Drugs. 1995;6(3):50-53.
45. Wen W, Lynch SY, Munera C, et al. Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis. Expert Opin Drug Saf. 2013;12(3):309-319.
46. Durand C, Alhanmmad A, Willett K. Practical considerations for optimal transdermal drug delivery. Am J Health Syst Pharm. 2012;69(2): 116-124.
47. FDA [homepage on the Internet]. Public Health Advisory: risk of burns during MRI scans from Transdermal drug patches with metallic backings. Available from: http://www.fda.gov/Drugs/DrugSafety/ Postm arketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInfor mationforHeathcareProfessionals/PublicHealthAdvisories/ucm111313. htm. Accessed May19,2014.
48. Hong I, Gabay M, Ladolce A. Safety concerns involving transdermal patches and magnetic resonance imaging (MRI). Hospital Pharmacy. 2010;45(10):771-778.
49. Southam MA. Transdermal fentanyl therapy: System design, pharmacokinetics and efficacy. Anticancer Drugs. 1995;6(Suppl3):29-34.
50. Portenoy RK, Southam M, Gupta SK, et al. Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics and efficacy. Anesthesiology. 1993;78(1):36-43.
51. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96(5): 627-632.
52. Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med. 2006;20(Suppl1):S3-S8.
53. Overholser BR, Foster DR. Opioid pharmacokinetic drug-drug interactions. Am J Manage Care. 2011;17(Suppl11):S276-S287.
54. McCance-Katz EF, Sullivan L, Nallani S. Drug interaction of clinical importance among the opioids, methadone, and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010;19(1):4-16.
55. Jumbelic MI. Deaths with transdermal fentanyl patches. Am J Forensic Med Pathol. 2010;31(1):18-21.
56. FDA [homepage on the Internet]. Safety warnings regarding use of fentanyl transdermal (skin) patches. Available from: http://www.fda. gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatien tsandProviders/DrugSafetyInformationforHeathcareProfessionals/ PublicHealthAdvisories/ucm051739.htm. Accessed May19,2014.
57. FDA [homepage on the Internet]. FDA issues second safety warning on fentanyl skin patch: deaths and serious injuries from improper use. Available from: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2007/ucm109046.htm. Accessed May19,2014.
58. FDA [homepage on the Internet]. FDA reminds the public about the potential for life-threatening harm from accidental exposure to fentanyl transdermal systems ("patches"). Available from: http://www.fda.gov/ drugs/drugsafety/ucm300747.htm. Accessed May19,2014.
59. FDA [homepage on the Internet]. FDA Drug Safety Communication: FDA requiring color changes to Duragesic (fentanyl) pain patches to aid safety-emphasizing that accidental exposure to used patches can cause death. Available from: http://www.fda.gov/drugs/drugsafety/ ucm368902.htm.Accessed May19,2014.
60. Heiskanen T, Matzke S, Haakana S, et al. Transdermal fentanyl in cachectic cancer patients. Pain. 2009;144(1-2):218-222.
61. van Ojik AL, Jansen PAF, Bruwers JR, van Roon EN. Treatment of chronic pain in older people evidence-based choice of strong-acting opioids. Drugs Aging. 2012;29(8):615-625.
62. Plosker Gl. Buprenorphine5,10, and20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain. Drugs. 2011;71(18):2491-2509.
63. Michel E, Anderson B, Zernikow B. Buprenorphine TTS for children-a review of the drug's clinical pharmacology. Paediatr Anaesth. 2011;21(3):280-290.
64. Zernikow B, Michel E, Craig F, Anderson BJ. Pediatric palliative care: use of opioids for the management of pain. Paediatr Drugs. 2009;11(2): 129-151.